심혈관 중재시술 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2026-2033년)
Interventional Cardiology Devices Market Size, Share & Trends Analysis Report By Product (Coronary Stents, PTCA Balloon Catheters, Intravascular Imaging Catheters & Pressure Guidewires, Accessory Devices), By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1941549
리서치사
:
Grand View Research
발행일
:
2026년 01월
페이지 정보
:
영문 150 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
심혈관 중재시술 기기 시장 요약
세계의 심혈관 중재시술 기기 시장 규모는 2025년에 112억 8,000만 달러로 추정되며, 2033년까지 197억 5,000만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 7.30%로 성장할 것으로 예상됩니다. 시장 성장의 주요 요인으로는 심혈관질환의 유병률 증가, 최소침습 수술에 대한 수요, 약물 용출 스텐트 및 생체흡수성 혈관 스캐폴드 등의 기술 발전 등을 들 수 있습니다.
고령화 인구 증가, 의료비 지출 증가, 신흥시장에서의 심장 의료 접근성 향상도 시장 확대에 기여하고 있습니다. 2025년 5월, 멘티스는 세계 20위권 의료 기술 기업으로부터 64만 2,000달러 규모의 수주 계약을 체결하여 중재적 심장학 시뮬레이션 훈련 솔루션을 확대했습니다. 이번 수주는 임상의의 숙련도와 환자 안전을 향상시키는 첨단 시술 훈련 도구에 대한 수요가 증가하고 있음을 보여줍니다.
심혈관질환의 유병률 증가는 심혈관 중재시술 기기 산업 성장의 주요 촉진요인입니다. 앉아서 생활하는 습관, 부적절한 식습관, 비만과 당뇨병의 증가율이 관상동맥질환을 비롯한 심장질환이 전 세계적으로 급증하고 있습니다. 이러한 질병 부담의 증가는 신속하고 효과적인 치료 개입에 대한 수요를 증가시켜 스텐트, 카테터 및 기타 중재적 치료 도구의 도입을 촉진하고 있습니다. 2024년 10월, 미국 질병예방통제센터(CDC)는 심장병이 2023년 91만 9,000명 이상, 전체 사망자의 약 3분의 1을 차지하며 미국 내 사망원인 1위로 나타났다고 발표했습니다. 34초마다 1명이 심혈관질환으로 사망하고 있으며, 성인의 약 5%가 관상동맥 질환의 영향을 받고 있습니다. 2020년부터 2021년까지 심장병은 의료비, 약품비, 생산성 손실로 인해 4,179억 달러의 경제적 부담을 초래했습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 세계의 심혈관 중재시술 기기 시장 변수, 동향 및 범위
제4장 세계의 심혈관 중재시술 기기 시장 세분화, 제품별, 2021-2033년
제5장 심혈관 중재시술 기기 시장 세분화, 지역별, 2021-2033년
제6장 경쟁 구도
KSM
영문 목차
Interventional Cardiology Devices Market Summary
The global interventional cardiology devices market size was estimated at USD 11.28 billion in 2025 and is projected to reach USD 19.75 billion by 2033, growing at a CAGR of 7.30% from 2026 to 2033. The market growth is driven by the rising prevalence of cardiovascular diseases, demand for minimally invasive procedures, and advancements in technologies such as drug-eluting stents and bioresorbable vascular scaffolds.
The expanding elderly population, rising healthcare spending, and improved access to cardiac care in emerging markets also contribute to market expansion. In May 2025, Mentice secured a USD 642,000 order from a top 20 global MedTech company to expand its simulation-based training solutions for interventional cardiology. The order highlights the growing demand for advanced procedural training tools designed to enhance clinician proficiency and patient safety.
The rising prevalence of cardiovascular diseases is a primary driver of the interventional cardiology devices industry growth. Sedentary lifestyles, poor dietary habits, and increasing rates of obesity and diabetes have led to a global surge in coronary artery disease and other cardiac conditions. This growing disease burden has increased the demand for timely and effective interventions, boosting the adoption of stents, catheters, and other interventional tools.In October 2024, the CDC reported that heart disease continues to be the top cause of death in the U.S., responsible for more than 919,000 deaths in 2023, or roughly one-third of all fatalities. A person dies from cardiovascular disease every 34 seconds, and around 5% of adults are affected by coronary artery disease. Between 2020 and 2021, heart disease incurred a financial toll of USD 417.9 billion in healthcare costs, medications, and lost productivity.
Global Interventional Cardiology Devices Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country-level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the global Interventional cardiology devices market report based on product and region:
Product Outlook (Revenue, USD Million, 2021 - 2033)
Coronary Stents
PTCA Balloon Catheters
Normal
Specialty
Drug-Coated
Intravascular Imaging Catheters and Pressure Guidewires
Accessory Devices
PTCA Guidewires
PTCA Guiding Catheters
Introducer Sheaths
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
Italy
Spain
France
Sweden
Denmark
Norway
Asia Pacific
China
India
Japan
Thailand
South Korea
Australia
Latin America
MEA
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Interventional Cardiology Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Global Interventional Cardiology Devices: Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTLE Analysis
3.4. Technology Landscape
3.5. Case Study Analysis
Chapter 4. Global Interventional Cardiology Devices Market Segment Analysis, By Product, 2021-2033 (USD Million)
4.1. Definition and Scope
4.2. Product Market Share Analysis, 2025 & 2033
4.3. Segment Dashboard
4.4. Global Interventional Cardiology Devices Market, by Product, 2021 to 2033
4.5. Coronary Stents
4.5.1. Coronary stents market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.2. DES
4.5.2.1. DES market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.3. BMS
4.5.3.1. BMS market estimates and forecasts, 2021 to 2033 (USD Million)
4.5.4. BRS
4.5.4.1. BRS market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. PTCA Balloon Catheters
4.6.1. PTCA balloon catheters market estimates and forecasts, 2021 to 2033 (USD Million)
4.6.2. Normal
4.6.2.1. Normal market estimates and forecasts, 2021 to 2033 (USD Million)
4.6.3. Specialty
4.6.3.1. Specialty market estimates and forecasts, 2021 to 2033 (USD Million)
4.6.4. Drug-Coated
4.6.4.1. Drug-coated market estimates and forecasts, 2021 to 2033 (USD Million)
4.7. Intravascular Imaging Catheters and Pressure Guidewires
4.7.1. Intravascular imaging catheters and pressure guidewires market estimates and forecasts, 2021 to 2033 (USD Million)
4.8. Accessory devices
4.8.1. Accessory devices market estimates and forecasts, 2021 to 2033 (USD Million)
4.8.2. PTCA Guidewires
4.8.2.1. PTCA guidewires market estimates and forecasts, 2021 to 2033 (USD Million)
4.8.3. PTCA Guiding Catheters
4.8.3.1. PTCA guiding catheters market estimates and forecasts, 2021 to 2033 (USD Million)
4.8.4. Introducer Sheaths
4.8.4.1. Introducer sheaths market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. Interventional Cardiology Devices Market Segment Analysis, By Region, 2021- 2033 (USD Million)
5.1. Regional Market Share Analysis, 2025 & 2033
5.2. Regional Market Dashboard
5.3. Regional Market Snapshot
5.4. Interventional Cardiology Devices Market Share by Region, 2025 & 2033
5.5. North America
5.5.1. North America Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.5.2. U.S.
5.5.2.1. Key Country Dynamics
5.5.2.2. Regulatory Scenario
5.5.2.3. Competitive Scenario
5.5.2.4. U.S. Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.5.3. Canada
5.5.3.1. Key Country Dynamics
5.5.3.2. Regulatory Scenario
5.5.3.3. Competitive Scenario
5.5.3.4. Canada Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.5.4. Mexico
5.5.4.1. Key Country Dynamics
5.5.4.2. Regulatory Scenario
5.5.4.3. Competitive Scenario
5.5.4.4. Mexico Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6. Europe
5.6.1. Europe Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.2. UK
5.6.2.1. Key Country Dynamics
5.6.2.2. Regulatory Scenario
5.6.2.3. Competitive Scenario
5.6.2.4. UK Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.3. Germany
5.6.3.1. Key Country Dynamics
5.6.3.2. Regulatory Scenario
5.6.3.3. Competitive Scenario
5.6.3.4. Germany Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.4. France
5.6.4.1. Key Country Dynamics
5.6.4.2. Regulatory Scenario
5.6.4.3. Competitive Scenario
5.6.4.4. France Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.5. Italy
5.6.5.1. Key Country Dynamics
5.6.5.2. Regulatory Scenario
5.6.5.3. Competitive Scenario
5.6.5.4. Italy Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.6. Spain
5.6.6.1. Key Country Dynamics
5.6.6.2. Regulatory Scenario
5.6.6.3. Competitive Scenario
5.6.6.4. Spain Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.7. Norway
5.6.7.1. Key Country Dynamics
5.6.7.2. Regulatory Scenario
5.6.7.3. Competitive Scenario
5.6.7.4. Norway Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.8. Sweden
5.6.8.1. Key Country Dynamics
5.6.8.2. Regulatory Scenario
5.6.8.3. Competitive Scenario
5.6.8.4. Sweden Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.6.9. Denmark
5.6.9.1. Key Country Dynamics
5.6.9.2. Regulatory Scenario
5.6.9.3. Competitive Scenario
5.6.9.4. Denmark Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7. Asia Pacific
5.7.1. Japan
5.7.1.1. Key Country Dynamics
5.7.1.2. Regulatory Scenario
5.7.1.3. Competitive Scenario
5.7.1.4. Japan Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7.2. China
5.7.2.1. Key Country Dynamics
5.7.2.2. Regulatory Scenario
5.7.2.3. Competitive Scenario
5.7.2.4. China Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7.3. India
5.7.3.1. Key Country Dynamics
5.7.3.2. Regulatory Scenario
5.7.3.3. Competitive Scenario
5.7.3.4. India Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7.4. Australia
5.7.4.1. Key Country Dynamics
5.7.4.2. Regulatory Scenario
5.7.4.3. Competitive Scenario
5.7.4.4. Australia Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7.5. South Korea
5.7.5.1. Key Country Dynamics
5.7.5.2. Regulatory Scenario
5.7.5.3. Competitive Scenario
5.7.5.4. South Korea Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.7.6. Thailand
5.7.6.1. Key Country Dynamics
5.7.6.2. Regulatory Scenario
5.7.6.3. Competitive Scenario
5.7.6.4. Thailand Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.8. Latin America
5.8.1. Brazil
5.8.1.1. Key Country Dynamics
5.8.1.2. Regulatory Scenario
5.8.1.3. Competitive Scenario
5.8.1.4. Brazil Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.8.2. Argentina
5.8.2.1. Key Country Dynamics
5.8.2.2. Regulatory Scenario
5.8.2.3. Competitive Scenario
5.8.2.4. Argentina Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.9. MEA
5.9.1. South Africa
5.9.1.1. Key Country Dynamics
5.9.1.2. Regulatory Scenario
5.9.1.3. Competitive Scenario
5.9.1.4. South Africa Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.9.2. Saudi Arabia
5.9.2.1. Key Country Dynamics
5.9.2.2. Regulatory Scenario
5.9.2.3. Competitive Scenario
5.9.2.4. Saudi Arabia Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.9.3. UAE
5.9.3.1. Key Country Dynamics
5.9.3.2. Regulatory Scenario
5.9.3.3. Competitive Scenario
5.9.3.4. UAE Interventional cardiology devices market, 2021 - 2033 (USD Million)
5.9.4. Kuwait
5.9.4.1. Key Country Dynamics
5.9.4.2. Regulatory Scenario
5.9.4.3. Competitive Scenario
5.9.4.4. Kuwait Interventional cardiology devices market, 2021 - 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company Categorization
6.3. Company Profiles
6.3.1. Abbott
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Product benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Medtronic
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Product benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Boston Scientific Corporation
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Product benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Cardinal Health, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Koninklijke Philips N.V.
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Terumo Corporation
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Alvimedica Medical Technologies Inc.
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Teleflex Incorporated
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. B. Braun Melsungen AG
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Biosensors International Group, Ltd.
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Meril Life Sciences Pvt. Ltd.
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. BIOTRONIK SE & Co. KG.
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives
6.3.13. ACIST Medical Systems, Inc.
6.3.13.1. Company overview
6.3.13.2. Financial performance
6.3.13.3. Product benchmarking
6.3.13.4. Strategic initiatives
6.3.14. Asahi Intecc Co., Ltd.
6.3.14.1. Company overview
6.3.14.2. Financial performance
6.3.14.3. Product benchmarking
6.3.14.4. Strategic initiatives
6.3.15. Cook Medical LLC
6.3.15.1. Company overview
6.3.15.2. Financial performance
6.3.15.3. Product benchmarking
6.3.15.4. Strategic initiatives
6.3.16. Medinol Ltd.
6.3.16.1. Company overview
6.3.16.2. Financial performance
6.3.16.3. Product benchmarking
6.3.16.4. Strategic initiatives
6.3.17. Merit Medical Systems, Inc.
6.3.17.1. Company overview
6.3.17.2. Financial performance
6.3.17.3. Product benchmarking
6.3.17.4. Strategic initiatives
6.3.18. NuMED, Inc.
6.3.18.1. Company overview
6.3.18.2. Financial performance
6.3.18.3. Product benchmarking
6.3.18.4. Strategic initiatives
6.3.19. OpSens Inc.
6.3.19.1. Company overview
6.3.19.2. Financial performance
6.3.19.3. Product benchmarking
6.3.19.4. Strategic initiatives
6.3.20. Zeon Medical Inc.
6.3.20.1. Company overview
6.3.20.2. Financial performance
6.3.20.3. Product benchmarking
6.3.20.4. Strategic initiatives
관련자료
